Mitovation’s story began in the labs of Drs. Maik Huttemann and Thomas Sanderson. Starting in 2006, they sought to understand the ways in which infrared light (IRL) of varying wavelengths interact with subcellular structures. This work led to the eventual discovery behind Mitovation’s unique technology: that specific wavelengths of infrared light can inhibit sub-cellular reactions in cells that have been reperfused after being denied blood flow and oxygen. This concept was initially confirmed by Drs. Huttemann and Sanderson in the lab, and eventually led to testing in small and large animal models of cardiac arrest/resuscitation as well as neonatal hypoxia/ischemia. To date, this work has confirmed infrared light’s neuroprotective effects on the brain. Animals treated with Mitovation therapy have less brain damage and better functional outcomes than control groups.
With the help of CEO Mark Morsfield, Drs. Huttemann and Sanderson founded the company in November of 2016 with the intent to translate this minimally invasive, groundbreaking technology to humans. With generous support from multiple granting agencies including the NIH and DoD, Mitovation’s team has been able to continue its ongoing investigation of IRL in multiple animal models, and start the design and development of a commercial prototype to be used in First-in-Man studies in the process of achieving FDA clearance.
Mitovation is currently seeking investment to accelerate the commercialization of our product. For more information, please provide your email below or fill out a form in the Contact section of our website.